Description
Cardarine (GW-501516) 10 mg Vital Research — cardarine (GW-501516) from Vital Research at 10 mg. PPAR-delta agonist (not a SARM). Drives mitochondrial biogenesis and fatty-acid oxidation. Endurance improvement without HPTA impact.
Key Benefits
- PPARδ agonist — technically NOT a SARM (no AR binding)
- Dramatic endurance enhancement — marathon-level cardio improvement
- Fatty-acid oxidation up; does not suppress HPTA
- No PCT required
- Cancer concerns from rodent studies at 20× human dose — decide with open eyes
- Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 10–20 mg/day, single daily dose or split. Cycles 8–12 weeks. Dose pre-cardio for acute enhancement.
How It Works
GW-501516, PPARδ (peroxisome proliferator-activated receptor delta) agonist. Mechanism unrelated to SARMs despite market grouping — does not touch AR. Upregulates fatty-acid oxidation, mitochondrial biogenesis, and muscle fibre-type remodeling.
Pharmacokinetics
Plasma half-life approximately 16–24 hours. Once-daily dosing. Steady-state 5 days.
Potential Side Effects
Clean for HPTA, liver, and lipids at research doses. Rodent carcinogenicity studies at supraphysiological doses (20× human equivalent) — interpret with context. No recommended human use outside research framing.
Cycle & Stacking Guide
Stacks with SARMs for recomp, or with AAS cycles for cardio support on compounds that hurt endurance (tren, trenbolone especially). Standalone during cutting phases.
Manufacturer Notes
Vital Research focuses on research compounds and support supplements with batch-specific quality control documentation.
Storage & Handling
Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.